Verve Therapeutics Inc., a Boston-based biotechnology company focusing on gene editing, captured investor attention this week due to encouraging results from its research. Specifically, the company's stock surged 12% following the announcement of the safety of its new treatment method for individuals with high cholesterol levels. The success of the clinical trial marks an important step forward for both the company and the industry as a whole.